Modification of paclitaxel-loaded solid lipid nanoparticles with 2-hydroxypropyl-β-cyclodextrin enhances absorption and reduces nephrotoxicity associated with intravenous injection

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 5397-5405

  Baek, Jong Suep ^a   Kim, Ju Heon ^a   Park, Jeong Sook ^a   Cho, Cheong Weon ^a  

^a Chungnam National University   (South Korea)

Author keywords

2 hydroxypropyl cyclodextrin; Bioavailability; Nephrotoxicity; Paclitaxel; Solid lipid nanoparticles

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; CREATININE; PACLITAXEL; SOLID LIPID NANOPARTICLE; 130-NM ALBUMIN-BOUND PACLITAXEL; 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; ALBUMINOID; ANTINEOPLASTIC AGENT; BETA CYCLODEXTRIN DERIVATIVE; DRUG CARRIER; LIPID; NANOPARTICLE;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; BREAST CANCER; CELL PROLIFERATION; CONFOCAL MICROSCOPY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RELEASE; DRUG UPTAKE; FLOW CYTOMETRY; IN VIVO STUDY; KIDNEY SIZE; MALE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR DYNAMICS; NEPHROTOXICITY; NONHUMAN; RAT; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; BLOOD; BREAST TUMOR; CANCER TRANSPLANTATION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; MCF-7 CELL LINE; MOUSE;

RATTUS;

ALBUMINS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AREA UNDER CURVE; BETA-CYCLODEXTRINS; BREAST NEOPLASMS; CELL PROLIFERATION; CELL SURVIVAL; CREATININE; DRUG CARRIERS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLOW CYTOMETRY; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY; LIPIDS; MALE; MCF-7 CELLS; MICE; MICE, INBRED BALB C; MICROSCOPY, CONFOCAL; NANOPARTICLES; NEOPLASM TRANSPLANTATION; PACLITAXEL; RATS;

EID: 84940092934     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S86474     Document Type: Article

References (35)

1. Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm. 2002;235:179-192
2. Yoncheva K, Calleja P, Agüeros M, et al. Stabilized micelles as delivery vehicles for paclitaxel. Int J Pharm. 2012;436:258-264
3. Lee SC, Huh KM, Lee J, Cho YW, Galinsky RE, Park K. Hydrotropic polymeric micelles for enhanced paclitaxel solubility: in vitro and in vivo characterization. Biomacromolecules. 2007;8:202-208
4. Kim SC, Kim DW, Shim YH, et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release. 2001;72:191-202
5. Sharma A, Mayhew E, Straubinger RM. Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model. Cancer Res. 1993;53:5877-5881
6. Bilensoy E, Gürkaynak O, Doğan AL, Hincal AA. Safety and efficacy of amphiphilic beta-cyclodextrin nanoparticles for paclitaxel delivery. Int J Pharm. 2008;347:163-170
7. Talegaonkar S, Azeem A, Ahmad FJ, Khar RK, Pathan SA, Khan ZI. Microemulsions: a novel approach to enhanced drug delivery. Recent Pat Drug Deliv Formul. 2008;2:238-257
8. Dordunoo SK, Jackson JK, Arsenault LA, Oktaba AM, Hunter WL, Burt HM. Taxol encapsulation in poly(epsilon-caprolactone) micro-spheres. Cancer Chemother Pharmacol. 1995;36:279-282
9. Sharma D, Chelvi TP, Kaur J, et al. Novel taxol formulation: polyvi-nylpyrrolidone nanoparticle-encapsulated taxol for drug delivery in cancer therapy. Oncol Res. 1996;8:281-286
10. Li X, Li P, Zhang Y, et al. Novel mixed polymeric micelles for enhancing delivery of anticancer drug and overcoming multidrug resistance in tumor cell lines simultaneously. Pharm Res. 2010;27:1498-1511
11. Luo J, Xiao K, Li Y, et al. Well-defined, size-tunable, multifunctional micelles for efficient paclitaxel delivery for cancer treatment. Bioconjug Chem. 2010;21:1216-1224
12. Xiao K, Luo J, Fowler WL, et al. A self-assembling nanoparticle for pacli-taxel delivery in ovarian cancer. Biomaterials. 2009;30:6006-6016
13. Prokop A, Davidson JM. Nanovehicular intracellular delivery systems. J Pharm Sci. 2008;97:3518-3590
14. Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for par-enteral drug delivery. Adv Drug Deliv Rev. 2004;56:1257-1272
15. Souto EB, Muller RH. Cosmetic features and applications of lipid nanoparticles (SLN, NLC). Int J Cosmet Sci. 2008;30:157-165
16. Lippacher A, Muller RH, Mader K. Investigation on the viscoelas-tic properties of lipid based colloidal drug carriers. Int J Pharm. 2000;196:227-230
17. Marengo E, Cavalli R, Caputo O, Rodriguez L, Gasco MR. Scale-up of the preparation process of solid lipid nanospheres. Part I. Int J Pharm. 2000;205:3-13
18. Mehnert W, Mader K. Solid lipid nanoparticles: production, character-ization and applications. Adv Drug Deliv Rev. 2001;47:165-196
19. Baek JS, So JW, Shin SC, Cho CW. Solid lipid nanoparticles of pacli-taxel strengthened by hydroxypropyl-β-cyclodextrin as an oral delivery system. Int J Mol Med. 2012;30:953-959
20. Baek JS, Cho CW. 2-Hydroxypropyl-β-cyclodextrin-modified SLN of paclitaxel for overcoing p-glycoprotein function in multidrug resistant breast cancer cells. J Pharm Pharmacol. 2013;65:72-78
21. Yamazaki M, Ito T. Deformation and instability in membrane structure of phospholipid vesicles caused by osmophobic association: mechanical stress model for the mechanism of poly(ethylene glycol)-induced membrane fusion. Biochemistry. 1990;29:1309-1314
22. Gratton SE, Ropp PA, Pohlhaus PD, et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A. 2008;105:11613-11618
23. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer. 1994;73:2013-2026
24. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674
25. Gao L, Liu G, Ma J, Wang X, Zhou L, Li X. In vivo performances. J Control Release. 2012;160:418-430
26. Lou H, Zhang X, Gao L, et al. In vitro and in vivo antitumor activity of oridonin nanosuspension. Int J Pharm. 2009;379:181-186
27. Gao L, Zhang D, Chen M, et al. Studies on pharmacokinetics and tis-sue distribution of oridonin nanosuspensions. Int J Pharm. 2008;355: 321-327
28. Moqhimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanopartricles: theory to practice. Pharmacol Rev. 2001;53: 283-318
29. Aliabadi HM, Shahin M, Brocks DR, Lavasanifar A. Disposition of drugs in block copolymer micelle delivery systems: from discovery to recovery. Clin Pharmacokinet. 2008;47:619-634
30. Haghighi M, Nematbakhsh M, Talebi A, et al. The role of angiotensin II receptor 1 (AT1) blockade in cisplatin-induced nephrotoxicity in rats: gender-related differences. Ren Fail. 2012;34:1046-1051
31. Nematbakhsh M, Ashrafi F, Safari T, et al. Administration of vitamin E and losartan as prophylaxes in cisplatin-induced nephrotoxicity model in rats. J Nephrol. 2012;25:410-417
32. Shimeda Y, Hirotani Y, Akimoto Y, et al. Protective effects of capsaicin against cisplatin-induced nephrotoxicity in rats. Biol Pharm Bull. 2005;28: 1635-1638
33. Evenepoel P. Acute toxic renal failure. Best Pract Res Clin Anaesthesiol. 2004;18:37-52
34. Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet. 2005;365:417-430
35. Koziara JM, Whisman TR, Tseng MT, Mumper RJ. In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. J Control Release. 2006;112:312-319.